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Takotsubo cardiomyopathy is a rare but increasingly recognized phenomenon, which can occur as a side-effect of chemotherapeutic
agents, in particular, the antimetabolite 5-fluorouracil. We describe a case of delayed Takotsubo cardiomyopathy after 3
weeks of adjuvant 5-fluorouracil for resected rectal adenocarcinoma in a 66-year-old female, supported by angiographic,
electrocardiographic, and echocardiographic features. As a complication, she developed an apical mural thrombus with subsequent
cerebral thromboembolic events and was successfully anticoagulated to make a full recovery. We present a review of the literature
on Takotsubo cardiomyopathy secondary to 5-fluorouracil and the rare occurrence of thromboembolic complications. As this is a
significant clinical phenomenon which involves a multispeciality approach to management, oncologists and cardiologists need to
recognize it as a potential toxicity of a widely administered chemotherapeutic drug.
1. Introduction
Takotsubo cardiomyopathy (TCM) as a result of expo-
sure to chemotherapeutic agents is a rare but increasing
phenomenon. TCM has been noted to occur primarily in
association with 5-fluorouracil (5-FU), but it has recently
been described with other chemotherapeutic agents such
as bevacizumab [1], cetuximab, rituximab, doxorubicin, and
cyclophosphamide (R-CHOP) combination [2]. The diagno-
sis of TCM is primarily based on criteria from the Mayo
Clinic [3], defined as transient left ventricular (LV) dys-
function extending beyond a single vascular territory, elec-
trocardiographic changes that can mimic acute myocardial
infarction, and minimal release of myocardial enzymes in
the absence of obstructive coronary artery disease or acute
plaque rupture. All the above criteria must occur in the
absence of recent significant head trauma, intracranial bleed-
ing, pheochromocytoma, obstructive epicardial coronary
artery disease, myocarditis, or hypertrophic cardiomyopathy.
We present a case of delayed TCM whilst receiving adjuvant
chemotherapy for rectal adenocarcinoma.
2. Case Presentation
A 66-year-old Caucasian woman with no previous cardiac
history or comorbidities was diagnosed with a rectal adeno-
carcinoma on colonoscopy performed as part of a workup for
iron-deficiency anaemia inAugust 2010. It was less than 12 cm
from the anal verge and staged as a T3N1M0 rectal tumor
on MRI and CT. She received short-course neoadjuvant
radiotherapy, consisting of five fractions of 25Gy, followed by
an ultralow anterior resection and a defunctioning ileostomy,
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Figure 1: ECG on admission showing marked QT prolongation of
640milliseconds and giantT-wave inversions in all leads exceptAVR
and AVL.
in October 2010. Histopathology revealed a poorly differ-
entiated adenocarcinoma with infiltration into perirectal
fat, with clear excision margins and 2 out of 21 lymph
nodes positive for malignancy. She proceeded to commence
adjuvant chemotherapy, consisting of four months of weekly
5-FUwith leucovorin according to themodified Roswell Park
Regimen.Dose of 5-FUwas 650mg (450mg/m2) weekly with
50mg of leucovorin. She tolerated the first two doses well.
She presented to the emergency department with fatigue,
anorexia, nausea, and vomiting after the third week of
chemotherapy, having been unwell since the third day after
this dose. She described decreased oral intake, but no change
in ileostomy output, and had been taking ondansetron with
partial symptom relief. Blood pressure on presentation was
102/70mmHgwith a sinus tachycardia of 135 bpm. Saturation
was 100% in room air, and she was afebrile. She had a postural
drop, from 100/75mmHg to 80/65mmHg on standing.
Examination was otherwise unremarkable, with no signs of
cardiac failure. Pathology revealed an increased creatinine of
190 𝜇mol/L (baseline 150 𝜇mol/L) with a urea of 11.5mmol/L.
She had a hypomagnesaemia of 0.3mmol/L and a troponin
I rise of 0.21mmol/L, peaking at 0.23mmol/L during admis-
sion. Chest X-ray revealed a normal heart size, and a renal
ultrasound revealed no evidence of obstruction. ECG (Fig-
ure 1) showed marked QT prolongation of 640 milliseconds
and giantT-wave inversions in all leads except AVR andAVL.
The widespread QT changes on ECG were thought to
be secondary to electrolyte derangement, and she received
aggressive fluid and magnesium replacement. However,
echocardiogram demonstrated severe systolic dysfunction
with akinesis of the apex. There was preservation of the
basal segments without evidence of outflow tract obstruction.
Ejection fraction was calculated to be 30% at rest. A mobile
echodensity was noted in the apex suggestive of a mural
thrombus (Figure 2). In view of the finding of a thrombus,
she was commenced on intravenous heparin. The working
diagnosis was TCM with cardiogenic shock, exacerbated by
dehydration.
She progressed with worsening vomiting and severe
vertigo unresponsive to antiemetics. She also developed
cerebellar signs, and, in view of the high likelihood of throm-
boembolic cerebral events, she proceeded with imaging with
a brain CT which was normal. Brain MRI, however, revealed
an embolic shower with a small acute infarct in the left
cerebellar hemisphere with possibly two further infarcts in
the mid aspect of the midbrain and high right posterior
parietal parafalcine cortex.
Her symptoms improved whilst on IV heparin. Renal
function normalized by day four of admission, and troponin
started to trend downwards. She underwent a coronary
angiogram, which revealed atheroma with no flow limiting
coronary artery disease, supporting the diagnosis of TCM.
Serial ECG demonstrated that the QT interval was shorten-
ing (485 milliseconds) and 𝑇-wave inversion was less pro-
nounced. Repeat echocardiography demonstrated improve-
ment of her left ventricular function to moderate segmental
systolic dysfunction. After appropriate anticoagulation, her
thrombus had resolved. She was transferred to rehabilitation
on day 10 with no residual neurological deficits.
She did not receive further chemotherapy, and her
ileostomy was reversed. Repeat ECG in March 2011 showed
residual T-wave inversions with a normal QT interval. LV
function was low-normal. Unfortunately, she developed local
sacral and distant hepatic recurrence inDecember 2011 which
was not amenable to radical curative surgery. She did receive
a short course of palliative irinotecan and bevacizumab
chemotherapy; however, this was ceased due to cumulative
toxicities of nausea, vomiting, and fatigue. She was managed
expectantly, yet she passed away in May 2013. She had not
developed any further cardiac complications. Her last cardiac
investigations in December 2011 showed normal ECG and
low-normal LV function.
3. Discussion
5-FU, a fluoropyrimidine, is used in a range of different
tumor groups including gastrointestinal, breast, ovarian, and
head and neck. In colorectal cancer, it was the mainstay of
adjuvant treatment prior to the use of doublet chemotherapy
with oxaliplatin, and it remains the gold standard of adjuvant
therapy in rectal cancer. 5-FU is an antimetabolite which
enters cells via facilitated uracil transport and is converted
to cytotoxic nucleotides. Its mechanisms of action include
inhibition of thymidylate transferase and incorporation into
DNA and RNA. Common toxicities include diarrhoea,
palmar-plantar erythrodysesthesia, stomatitis, and myelo-
suppression. Gaveau et al. first described adverse cardiac
effects of 5-FU in 1969 [4], and this was again confirmed by
Carpenter in 1972 [5].
High-dose infusional 5-FU was found to have a greater
risk of cardiotoxicity, as reported in a prospective trial by de
Forni et al. in 1992 [6]. Within the literature, up to 18% of
patients are reported to develop cardiac complications after
administration of 5-FU [7]. To the knowledge of the authors,
there are nine previous case reports of 5-FU-induced TCM,
but only two other cases occurred after multiple doses [8].
Gianni et al. [9] reported a case of TCM occurring after 5-
Fluorouracil has been administered for a total of ten times.
Kobayashi et al. report a case of cardiac failure occurring after
5-FU for rectal adenocarcinoma with the same regimen as
that of our patient, which occurred four weeks after starting
treatment [10].
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Figure 2: Echocardiogram showed a severely dilated left ventricular apex with associated thrombus.
TCM does not appear to be related to timing of 5-FU.
Basselin et al. [11] described a 48-year-old man who devel-
oped TCM twenty-four hours after receiving the first dose of
FOLFOX (5-FU in combinationwith oxaliplatin) chemother-
apy for colon adenocarcinoma. Grunwald described a similar
case in a 60-year-old woman who developed TCM twenty-
six hours after the first infusion of 5-FU as part of FOLFOX
[8]. Delayed response to 5-FU has previously been reported
in the literature, as cardiac complications have been described
up to 1 month after discontinuation of 5-FU [12]. A delayed
case of TCM three months following 5-FU and cisplatin
for oesophageal squamous cell carcinoma was described by
Gangadhar et al., and it is believed to be the first case of
chemotherapy-induced TCM in the literature [13].
The mechanism behind delayed response to 5-FU is
undefined. It has been previously noted that 5-FU clearance
was found to be significantly lower in women [14], and
also compounding this, the active catabolites of 5-FU are
reported to be involved in cardiotoxicity [15]. Whether the
pharmacokinetics of 5-FU interacts with the underlying
mechanism of TCM in postmenopausal women is unclear,
but they may relate to similar physiological mechanisms.
Mechanisms that have been proposed include post-
menopausal alteration of endothelial function in response to
reduced estrogen levels thatmay explain the predominance in
older women [16]. There have been several theories relating
to sex hormones and their action on the sympathetic neu-
rohormonal axis as well as on coronary vasoreactivity [17].
A number of features of TCM, including its association with
physical or emotional stress, suggest that this disorder may
be caused by diffuse catecholamine-induced microvascular
spasm or dysfunction, resulting in myocardial stunning [18],
or by direct catecholamine-associated myocardial toxicity.
Data on recovery from TCM is variable and has been
suggested to vary from a matter of days [19] to the order of
3 to 6 months [18]. We recognize that our case was unusual
due to a longer time to full recovery, but that may reflect
other systemic factors whichmay have been influenced by the
complications that developed in our patient.
Current treatment of TCM consists of supportive care
and standard treatments for LV systolic dysfunction. The
role of anticoagulation therapy has not yet been defined.
There is inadequate literature relating to the rate of embolic
events and duration of anticoagulation within the TCM
patient population, but in several case reports patients were
transiently anticoagulated until full resolution of LV function.
Theuse of anticoagulation to prevent embolization in patients
with known LV thrombus is supported by indirect data
from observational studies in patients with LV thrombus
after myocardial infarction. In these studies, anticoagulation
during a period of four to six months was associated with a
reduced rate of embolization [20].
Our case was complicated by development of left ven-
tricular thrombus and subsequent embolic stroke. Kurisu
et al. reported an incidence of 5.3% of apical thrombus,
and within this series there was a case report of one
patient undergoing a neurological event [21]. Haghi et al.
reported an 8% incidence of LV thrombus, but a much lower
incidence of accompanying embolic complications [22]. de
Gregorio described morphological characteristics associ-
ated with increased thrombus-related embolic complications.
He concluded that women >65 years of age presenting
with deep/giant negative 𝑇-waves on admission ECG seem
more likely to have thrombus-related embolic complications,
which is consistent with our patient’s presentation [23].
4. Conclusion
TCMhas been increasingly noted to occur in associationwith
5-FU. This appears to bear no relationship to dosing interval
or cumulative dose. TCM can rarely be complicated by
thrombus-related embolic events, and current management
has yet to be standardized; however, there is indirect data for
the use of anticoagulation. As TCM is a significant clinical
phenomenon which involves a multispeciality approach to
management, oncologists and cardiologists need to recog-
nize this as a potential toxicity of a widely administered
chemotherapeutic drug.
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